The U.S. Food and Drug Administration (FDA) has approved two new biosimilars as reference products for Prolia (denosumab) and XGEVA® (denosumab): Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo ...
The FDA has designated Conexxence and Bomyntra as interchangeable biosimilars to the reference products Prolia and Xgeva, ...
Richter and Hikma have received the green light from the Food and Drug Administration for their biosimilar denosumab products, Enoby (denosumab-qbde) and Xtrenbo (denosumab-qbde), referencing Prolia ...
Findings showed denosumab-kyqq demonstrated similar quality, safety, and efficacy to the reference product. Bosaya is approved to treat postmenopausal women with osteoporosis at high risk for fracture ...
On September 16, 2025, the FDA approved Biocon Biologics Ltd.’s BOSAYA™ (denosumab-kyqq) and AUKELSO™ (denosumab-kyqq) as biosimilars to Amgen’s PROLIA ® and XGEVA ®, respectively. Both biosimilars ...
Findings showed denosumab-qbde demonstrated comparable quality, efficacy, safety, and immunogenicity to the reference product. Enoby is approved to treat postmenopausal women with osteoporosis at high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback